-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
-
Cosmetic Ingredient
- Water Treatment Chemical
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
Artery Network learned for the first time that Kekai (Nantong) Life Sciences Co.
, Ltd.
(hereinafter referred to as "Kekai Life Sciences") announced that it has received 350 million yuan in Pre-C round of financing
.
This round of financing was led by BOCG Blue Ocean and Shanghai Free Trade Zone Fund.
Kekai (Nantong) Life Sciences Co.
According to reports, Kekai Life Sciences is an innovative enterprise in the research and development of structural heart disease treatment products in China.
The company has developed a number of cardiovascular interventional products with independent intellectual property rights
.
At present, many of its products have been finalized and conducted multiple rounds of animal experiments, which initially verified the safety and effectiveness of the products
Valve interventional therapy is another hot track of interventional therapy after TAVR industry
.
As the industry is still in its infancy and the gap between domestic and foreign companies is even smaller, it is expected that domestically-made leading companies will emerge in the valve intervention market in the future, sharing the vast domestic and foreign markets
For patients with mitral valve regurgitation who are contraindicated in surgical operations or who cannot tolerate surgical operations, Kekai Life Sciences independently developed and created a mitral valve repair system suitable for domestic patients on the basis of the principle of edge-to-edge repair.
LIFECLIP®
.
The product has now completed the enrollment of many clinical patients, and the degree of mitral valve regurgitation in patients has been significantly improved after the operation, and there are no complications, which preliminarily confirms the clinical safety and effectiveness of LIFECLIP®
At the clinical level of the product, in addition to the successful development of LIFECLIP® and entering the clinic, KokaClip's transfemoral mitral valve repair system KokaClip® and transfemoral replacement valve KokaValve® have unique technical advantages and characteristics, and have passed ethics.
And is about to enter the clinical stage
.
The company also has a mitral valve annulus repair technology platform, and the mitral valve annulus production site has passed the project approval of Zhangjiang Park
Mr.
Yang Feng, founder of BOCG Blue Ocean Capital, said: “Cardiovascular diseases, especially heart valve diseases, are one of the diseases with the highest incidence and fatality rate in the world, and there is still a large unmet clinical demand
.
As a company with A medical device company with a global perspective, the team has rich industry experience and excellent R&D and innovation capabilities in the field of structural heart health; BOCG Blue Ocean Capital is very honored to lead this round of investment, and work with new and old shareholders to help Kekai in medical Continue to innovate in the device field, accelerate the clinical and commercialization of products, and provide safer and more effective medical devices and treatment options for patients around the world
Mr.
Mr.
Head of Zhang Ke Herun Fund
Mr.
Xiang Jun, Vice President of China Industrial Securities Innovation Capital, said: “With the advancement of medical device technology, the unique advantages in the field of valve repair systems have become increasingly prominent
.
The Kekai Life Science team uses its leading mitral valve repair system development practical experience and Innovative capabilities are growing into one of the leading companies in this field in China
.
In the past three years, Kekai Life Sciences has achieved more than expected development, and its pipeline R&D, clinical, production preparation, corporate business and financing capabilities have performed well in many aspects.
I am very happy to be able to participate in the accelerated development of the company, and look forward to Kekai Life Sciences continuing to be supported by technological innovation capabilities, leading the industry and benefiting mankind!"Mr.
Xiang Jun, Vice President of China Industrial Securities Innovation Capital
Ms.
Zhang Tong, Investment Manager of Interchina Capital, said: “The Kekai Life Science team has the strength of R&D pipelines and has been recognized by domestic heavyweight investment institutions, and will be selected as a GEI China potential unicorn enterprise in 2020.
Interchina
also follows our The consistent >
.
"
Zhang Tong, Investment Manager of Interchina Capital
About Kekai Life Science
About Kekai Life Science Kekai (Nantong) Life Science Co.
, Ltd.
was established in September 2018.
It is a high-tech enterprise focusing on the research and development, production and sales of medical devices in the field of structural heart disease.
It develops for different groups of people, different needs, and different scenarios.
System solutions for valvular diseases
.
The company's technical team is mainly centered on R&D personnel returning from the United States and Germany.
It has decades of development and research experience in the field of cardiac medicine
.
The technical level is in an absolute leading position in China and is synchronized with the most advanced cardiac medical treatment technology in the world .
In 2021, the company was selected as one of China's top 100 innovative medical devices sponsored by Zhong Nanshan Medical Foundation and others, and in 2020, it was selected as a potential unicorn company in China by GEI
.
About BOCG Blue Ocean Capital
About BOCG Blue Ocean Capital BOCG Blue Ocean Capital focuses on the growth phase and M&A investment of innovative biomedical and medical device companies in the medical and health field; the core team has rich international experience in scientific research, industry and investment, and manages multiple RMB and USD dual currency funds , Investment has won industry awards; BOCG Blue Ocean Capital insists on in-depth investment and value creation.
Through effective investment management, it brings positive changes to the invested companies and creates long-term value for investors
.
BOCG Blue Ocean Capital’s recent investment cases include HighTide Therapeutics, a research and development company focusing on original innovative drugs in the field of chronic liver disease, gastrointestinal disease and metabolism, and Suzhou Ribo Life Science Co.
, Ltd.
), a biomedical research and development company focusing on small nucleic acid innovation technology and small nucleic acid drug research and development, and Bo'an Biotech, a company that focuses on the development of therapeutic antibodies, focusing on oncology, autoimmunity, pain and endocrine Disease comprehensive biopharmaceutical company
.
About the Shanghai Free Trade Zone Fund
About the Shanghai Free Trade Zone Fund The Shanghai Free Trade Zone Fund is the country's first free trade zone-themed investment fund approved and established by the China (Shanghai) Pilot Free Trade Zone Management Committee under the new situation of the country on building a pilot free trade zone, comprehensively deepening reforms and expanding opening up
.
The Shanghai Free Trade Zone Fund was jointly initiated and established in 2015 by the financial holding group under the Ministry of Finance and the core function development entity of Shanghai International Finance, Shipping and Trade Center.
A market-oriented comprehensive investment platform where industrial and financial resources gather efficiently
.
About China Industrial Securities Innovation Capital
About China Industrial Securities Innovation Capital China Industrial Securities Innovation Capital Management Co.
, Ltd.
(hereinafter referred to as "China Industrial Securities Capital") is a private equity investment fund subsidiary wholly-owned by Industrial Securities Co.
, Ltd.
(SH601377), formerly known as the Direct Investment Department of Industrial Securities, managed through financial advisory in 2008 The first equity investment fund was approved to carry out direct investment business in 2010.
In April 2010, it officially became a subsidiary of Industrial Securities, with a registered capital of 700 million yuan, registered in Fuzhou City, Fujian Province, and its business scope is private equity investment fund business
.
About Zhangjiang Herun Fund (Zhangke Herun Fund)
About Zhangjiang Herun Fund (Zhangke Herun Fund) Zhangke Herun Fund is funded by Zhangjiang Technology Investment, a wholly-owned subsidiary of Zhangjiang Group.
The fund focuses on high-quality companies with growth potential in life and health-related industries such as innovative drugs, medical devices, and medical services
.
Zhangke Herun Fund, with the Pudong Science and Technology Fund of Funds as the cornerstone investor, introduces social capital and professional power, and operates the sub-funds that are invested and managed in a market-oriented manner, with a mechanism closer to the market and a more optimized investment process.
To match the growing financing needs of small and medium-sized science and innovation enterprises, and to promote the leap-forward development of technological innovation
.
About Interchina Capital
About Interchina Capital Interchina Capital currently manages two physical funds of the National SME Development Fund.
Its subsidiary Interchina Venture Capital (ie Shenzhen Interchina Venture Capital Management Co.
, Ltd.
) manages the first entity fund of the National SME Development Fund.
Rong Asset Management Co.
, Ltd.
) manages the second phase of the National Small and Medium-sized Enterprise Development Fund, and the total management scale has exceeded 10 billion yuan
.
Interchina Capital advocates the investment philosophy of research first, investment and research integration, and guides investment through in-depth research on the industry chain, focusing on investment opportunities in strategic emerging industries, focusing on big data, cloud computing, network security and corporate services, semiconductors, and electronic information technology.
Excellent companies in the fields of artificial intelligence, new consumption and Internet applications, new energy vehicles and smart driving, new materials, new energy, ecological and environmental protection and smart equipment, biomedicine and general health
.
